Patent Insights · Cross-Modality Analysis

Oral Macrocycle Scaffolds and Exposure Design: IL-23R Peptides vs TNFα Polycyclic Compounds

A comparison of six public applications shows where cyclic peptide strategies and rigid polycyclic small-molecule strategies address similar discovery questions—and where their chemistry and evidence must remain separate.

The Answer First

What Can Be Compared Across These Patent Families?

The three IL-23R applications disclose peptide-based antagonists with cyclic recognition elements and various appended groups. The three TNFα applications disclose polycyclic or azapolycyclic heterocyclic small molecules, not bicyclic or multicyclic peptides. A useful cross-patent comparison therefore asks how each modality builds a constrained target-binding scaffold and manages exposure, while keeping the chemical structures, assays and pharmacokinetic claims distinct.

This article extends our IL-23R cyclic peptide patent analysis. That page examines the three peptide applications individually. Here, the TNFα series provides a cross-modality reference for rigid scaffold design and target-specific validation. The comparison is relevant to an oral macrocycle design team because it clarifies which principles transfer at the level of project questions—binding interface, selectivity, developability—and which methods do not transfer directly across peptide and small-molecule chemistry.

Scope of the term “polycyclic”: in the TNFα applications it denotes fused or bridged heterocyclic small-molecule structures. It does not mean that the patents claim TNFα-targeting cyclic peptides. Likewise, the IL-23R long-chain embodiments should not all be called a confirmed C18 fatty-acid product.

Six Public Applications

Map the Evidence Before Comparing Routes

PatentModality and targetDesign focus in this readingWhat the publication does not establish by itself
WO2026067838A1IL-23R polypeptide / cyclic peptideConstrained peptide recognition scaffold and residue choicesA universally optimal oral scaffold or clinical efficacy
WO2026041110A1IL-23R polypeptide with appendage embodiments4-(p-iodophenyl)butyric acid (IPBA) appears in synthetic examplesThat IPBA is a fatty acid or alone proves half-life extension
WO2026130480A1IL-23R peptide antagonistAlternative linker and substituent groups, including illustrated long-chain embodimentsThat every claimed compound is the same C18 conjugate
WO2026021586A1TNFα polycyclic heterocyclic small moleculeRigid polycyclic scaffold as a TNFα modulatorPeptide-like cyclization or oral clinical performance
WO2026149469A1TNFα polycyclic heterocyclic small moleculeFurther polycyclic formula and substitution spaceA formal improvement of every earlier TNFα example
WO2026189524A1TNFα azapolycyclic small moleculeNitrogen-containing polycyclic framework and activity-modulation assaysAn IL-23R peptide program or a validated oral macrocycle

The numbers represent separate published applications. Similar applicants or target indications do not automatically establish a single patent family, sequential medicinal-chemistry lineage, equivalent potency, or a granted claim.

The Peptide Side

IL-23R: Scaffold First, Then Consider Exposure-Related Modifications

Recognition

Constrained Peptide Scaffold

Start with the precise cyclic connection, residue identity and side-chain presentation. A generic formula covers many variants; a compound-level analysis links a particular sequence and ring topology to a measured binding or functional readout. When exploring a new IL-23R peptide, target-interface assessment and a focused library can identify candidate recognition motifs, but a modeled complex remains a hypothesis until checked experimentally.

Appendage

IPBA Is Not a Fatty Acid

WO2026041110A1 explicitly describes 4-(p-iodophenyl)butyric acid in multiple synthesis steps. This aromatic group creates a different chemical question from a long aliphatic chain. Its point of attachment, linker architecture and effect on receptor activity should be compared with the unmodified parent. Albumin-containing activity assays can be informative, but do not alone quantify albumin binding, free fraction or in vivo residence time.

Exposure

Long-Chain Options Need Exact Structures

WO2026130480A1 illustrates a long hydrocarbon chain with a terminal carboxyl group in one part of its submitted application, alongside other substituent choices. The appropriate analysis indexes each candidate's actual attachment and chain structure to its assay data. The term C18 appears frequently in purification methods as a chromatography medium; those occurrences cannot establish an 18-carbon drug appendage.

For oral development, long systemic half-life and oral absorption are separate endpoints. A larger hydrophobic appendage may change solubility, membrane behavior, protein binding and clearance in competing directions. An oral cyclic peptide strategy should therefore define whether the immediate problem is intestinal transport, stability, target potency, or insufficient systemic exposure and then choose experiments that distinguish among them.

The Small-Molecule Side

TNFα: Compare Rigid Polycyclic Frameworks Within Their Own Chemistry

WO2026021586A1 and WO2026149469A1

The public abstracts describe polycyclic compounds for modulating human TNFα activity. Their chemical classifications and formula descriptions place them in heterocyclic small-molecule space. For a medicinal-chemistry team, the comparison should focus on ring fusion or bridging, heteroatom placement, stereochemical options and substituent positions, with assays evaluated under matched conditions. “More rings” does not itself prove stronger target modulation or better developability.

The two applications have different priority and publication dates. They can be discussed as related research directions associated with TNFα modulation, but one should not infer that every structure in the later application was derived from a specific earlier example without a compound-by-compound and priority-family analysis.

WO2026189524A1

This later-published application is titled “Azapolycyclic compound, preparation method therefor and use thereof.” Its abstract identifies nitrogen-containing polycyclic structures as modulators of human TNFα activity. The public text describes a fluorescence-polarization binding experiment, among other disclosed evaluations. The relevant service question is how structural changes alter target engagement and selectivity, followed by property and exposure assessment for the actual compounds.

The presence of an azapolycyclic formula is not evidence of a peptide backbone. Nor should in vitro TNFα modulation be described as demonstrated oral efficacy. For any candidate, the chemistry, assay endpoint and development claim must be tied to the same specific embodiment.

Transferable Lessons

Shared Research Questions, Different Experimental Answers

QuestionIL-23R cyclic peptide routeTNFα polycyclic small-molecule routeDecision evidence
How is binding geometry constrained?Residue sequence, cyclization chemistry, ring size, stereochemistry and conformer ensembleFused or bridged heterocycle, heteroatom pattern and three-dimensional substituent vectorsStructure-guided hypothesis plus target-binding and functional tests
Where can optimization be introduced?Side-chain and backbone edits, scaffold hopping, linker or appendage positionCore heterocycle and substitution-site changes within a synthetic seriesMatched analog series with potency, selectivity and synthesis data
What is an exposure strategy?Permeability and stability optimization; optional protein-binding or long-chain modificationSmall-molecule ADMET and PK optimization for each scaffoldMeasured permeability, free fraction, clearance and route-specific exposure
What is not transferable?A peptide's cyclization or conjugation workflowA small molecule's ring-fusion synthetic routeModality-specific feasibility and structural verification
Cross-patent comparison is a research framework, not an equivalence claim. Different targets, chemical modalities and assay formats prevent a direct ranking of the six patents by a single potency or “oral potential” score. A useful comparison defines the decision, normalizes only like-for-like data and records what remains unknown.

Services and Next Steps

Turn Patent Questions Into a Testable Project Plan

Target and Interface Assessment

For a peptide campaign, map the IL-23R interaction region, assess differentiating contacts and design a constrained library. For TNFα small-molecule questions, use an appropriate small-molecule structure and assay workflow rather than a peptide library.

Cyclic peptide library design →

Oral Developability

Compare ring and side-chain changes against potency, permeability, solubility, metabolic stability and synthesis feasibility. Keep any half-life-extending appendage as a separately tested hypothesis and evaluate it alongside oral absorption.

Oral cyclic peptide design →

Experimental Confirmation

Prioritize a small matched set for correct topology or structure, target binding, pathway function, albumin-related measurements where relevant, and PK. Use measured evidence to update the next design round.

Experimental validation →

Explore a Defined Design Question

Share the target, modality, starting compounds and the endpoint that matters most. We can scope a peptide-specific discovery or optimization plan and identify which cross-patent insights are relevant to that decision.

Discuss a project →

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.